ZYME Zymeworks Inc.
Nasdaq · SEC CIK 1937653 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $4.67M 8 sales by 4 insiders
- Filings on record
- 97 since 2022-10-17, latest 2026-07-06 17:29
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Galbraith Kenneth | COB, CEO, Dir | — | $3.34M |
| Moore Paul Andrew | CSO | — | $721.5K |
| Smith Jeffrey T L | EVP, Chief Medical Off | — | $475.6K |
| Hollywood Mark | EVP, COO | — | $138.7K |
| PATTERSON LEONE D | EVP, Chief Bus, Fin Off | — | — |
Transactions 66
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 17:29 | 2026-07-06 | ZYME | Hollywood Mark | EVP, COO | A - Grant | $22.22 | +939 | 133.9K | +0.7% | +$20.9K | |
| D | 2026-01-13 | 2026-01-12 | ZYME | Hollywood Mark | EVP, COO | M - OptEx | $0.00 | +17.7K | 139.0K | +15% | $0 |
| D | 2026-01-13 | 2026-01-12 | ZYME | Hollywood Mark | EVP, COO | S - Sale+OE | $22.67 | -6,120 | 132.9K | -4% | -$138.7K |
| D | 2026-01-12 | 2026-01-12 | ZYME | Moore Paul Andrew | CSO | M - OptEx | $0.00 | +17.7K | 58.1K | +44% | $0 |
| D | 2026-01-12 | 2026-01-12 | ZYME | Moore Paul Andrew | CSO | S - Sale+OE | $22.67 | -9,560 | 48.5K | -16% | -$216.7K |
| D | 2026-01-12 | 2026-01-12 | ZYME | Galbraith Kenneth | COB, CEO, Dir | M - OptEx | $0.00 | +64.0K | 257.3K | +33% | $0 |
| D | 2026-01-12 | 2026-01-12 | ZYME | Galbraith Kenneth | COB, CEO, Dir | S - Sale+OE | $22.67 | -30.4K | 226.8K | -12% | -$689.7K |
| D | 2026-01-12 | 2026-01-12 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Off | M - OptEx | $0.00 | +17.7K | 36.0K | +96% | $0 |
| D | 2026-01-12 | 2026-01-12 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Off | S - Sale+OE | $22.67 | -9,310 | 26.7K | -26% | -$211.1K |
| 2026-01-07 | 2026-01-06 | ZYME | PATTERSON LEONE D | EVP, Chief Bus, Fin Off | A - Grant | $10.55 | +459 | 459 | New | +$4,842 | |
| DM | 2026-01-05 | 2026-01-05 | ZYME | Galbraith Kenneth | COB, CEO, Dir | M - OptEx | $0.00 | +114.3K | 225.0K | +103% | $0 |
| DM | 2026-01-05 | 2026-01-05 | ZYME | Galbraith Kenneth | COB, CEO, Dir | S - Sale+OE | $25.10 | -54.3K | 158.3K | -26% | -$1.36M |
| DM | 2026-01-05 | 2026-01-05 | ZYME | Moore Paul Andrew | CSO | S - Sale+OE | $25.10 | -20.1K | 31.2K | -39% | -$504.8K |
| DM | 2026-01-05 | 2026-01-05 | ZYME | Moore Paul Andrew | CSO | M - OptEx | $0.00 | +37.2K | 51.2K | +265% | $0 |
| D | 2026-01-05 | 2026-01-05 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Off | M - OptEx | $0.00 | +20.0K | 28.9K | +225% | $0 |
| D | 2026-01-05 | 2026-01-05 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Off | S - Sale+OE | $25.10 | -10.5K | 18.4K | -36% | -$264.5K |
| D | 2025-12-22 | 2025-12-22 | ZYME | Galbraith Kenneth | COB, CEO, Dir | S - Sale+OE | $27.02 | -47.5K | 133.3K | -26% | -$1.28M |
| D | 2025-12-22 | 2025-12-22 | ZYME | Galbraith Kenneth | COB, CEO, Dir | M - OptEx | $0.00 | +100.0K | 180.8K | +124% | $0 |
| D | 2025-08-12 | 2025-08-12 | ZYME | Ciongoli Gregory Austin | Dir | A - Grant | $12.02 | +415.0K | 488.5K | +565% | +$4.99M |
| DI | 2025-06-27 | 2025-06-26 | ZYME | NODELMAN OLEG | Dir, 10% | X - OptEx | $0.00 | +5.09M | 22.97M | +28% | $0 |
| DI | 2025-06-27 | 2025-06-26 | ZYME | NODELMAN OLEG | Dir, 10% | F - Tax | $12.71 | -41 | 22.97M | -0.0% | -$521.11 |
| MI | 2025-05-19 | 2025-05-15+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $11.47 | +55.4K | 17.88M | +0.3% | +$635.5K |
| MI | 2025-04-18 | 2025-04-16+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $11.31 | +128.7K | 17.83M | +0.7% | +$1.46M |
| MI | 2025-04-07 | 2025-04-03+ | ZYME | NODELMAN OLEG | Dir, 10% | P - Purchase | $11.43 | +317.2K | 17.70M | +2% | +$3.62M |
| MI | 2025-04-02 | 2025-03-31+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $11.75 | +127.4K | 17.26M | +0.7% | +$1.50M |
| MI | 2025-03-27 | 2025-03-25+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $12.61 | +97.3K | 17.21M | +0.6% | +$1.23M |
| MI | 2025-03-24 | 2025-03-20+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $12.92 | +127.2K | 17.16M | +0.7% | +$1.64M |
| MI | 2025-03-19 | 2025-03-17+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $12.54 | +228.5K | 16.86M | +1% | +$2.87M |
| MI | 2025-03-13 | 2025-03-11+ | ZYME | NODELMAN OLEG | Dir, 10% | P - Purchase | $12.12 | +1.08M | 16.04M | +7% | +$13.12M |
| MI | 2025-01-21 | 2025-01-16+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $13.89 | +141.4K | 15.72M | +0.9% | +$1.96M |
| MI | 2025-01-15 | 2025-01-13+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $13.59 | +167.7K | 15.49M | +1% | +$2.28M |
| MI | 2025-01-10 | 2025-01-08+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $13.22 | +225.1K | 15.21M | +2% | +$2.98M |
| D | 2025-01-06 | 2025-01-06 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Off | M - OptEx | $0.00 | +20.0K | 20.0K | New | $0 |
| D | 2025-01-06 | 2025-01-06 | ZYME | Smith Jeffrey T L | EVP, Chief Medical Off | S - Sale+OE | $14.92 | -11.1K | 8,890 | -56% | -$165.8K |
| DM | 2025-01-06 | 2025-01-06 | ZYME | Moore Paul Andrew | CSO | M - OptEx | $0.00 | +37.2K | 24.5K | New | $0 |
| DM | 2025-01-06 | 2025-01-06 | ZYME | Moore Paul Andrew | CSO | S - Sale+OE | $14.92 | -21.2K | 14.7K | -59% | -$316.3K |
| DM | 2025-01-06 | 2025-01-06 | ZYME | Galbraith Kenneth | COB, CEO, Dir | S - Sale+OE | $14.92 | -57.3K | 80.8K | -41% | -$854.8K |
| DM | 2025-01-06 | 2025-01-06 | ZYME | Galbraith Kenneth | COB, CEO, Dir | M - OptEx | $0.00 | +114.3K | 71.4K | New | $0 |
| MI | 2025-01-02 | 2024-12-30+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $14.65 | +363.4K | 15.03M | +2% | +$5.32M |
| MI | 2024-12-27 | 2024-12-24+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $14.44 | +130.3K | 14.70M | +0.9% | +$1.88M |
| MAI | 2024-12-26 | 2024-12-19+ | ZYME | EcoR1 Capital, LLC | Dir, 10% | P - Purchase | $13.98 | +1.25M | 13.74M | +10% | +$17.55M |
| DM | 2024-01-08 | 2024-01-05+ | ZYME | Moore Paul Andrew | CSO | S - Sale+OE | $10.79 | -9,799 | 9,706 | -50% | -$105.7K |
| D | 2024-01-08 | 2024-01-05 | ZYME | Moore Paul Andrew | CSO | M - OptEx | $0.00 | +17.2K | 17.2K | New | $0 |
| D | 2024-01-08 | 2024-01-05 | ZYME | Astle Christopher | SVP, CFO | M - OptEx | $0.00 | +10.5K | 12.5K | +526% | $0 |
| DM | 2024-01-08 | 2024-01-05+ | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $10.79 | -5,994 | 7,934 | -43% | -$64.7K |
| D | 2024-01-08 | 2024-01-05 | ZYME | Galbraith Kenneth | COB, CEO, Dir | M - OptEx | $0.00 | +47.7K | 47.7K | New | $0 |
| DM | 2024-01-08 | 2024-01-05+ | ZYME | Galbraith Kenneth | COB, CEO, Dir | S - Sale+OE | $10.79 | -23.9K | 29.5K | -45% | -$257.8K |
| D | 2023-12-11 | 2023-12-11 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $9.13 | -886 | 1,997 | -31% | -$8,089 |
| D | 2023-12-11 | 2023-12-11 | ZYME | Astle Christopher | SVP, CFO | M - OptEx | $0.00 | +1,550 | 2,883 | +116% | $0 |
| I | 2023-06-21 | 2023-06-16 | ZYME | EcoR1 Capital, LLC | 10% | P - Purchase | $8.12 | +3.35M | 13.44M | +33% | +$27.20M |
| I | 2023-03-30 | 2023-03-28 | ZYME | EcoR1 Capital, LLC | 10% | P - Purchase | $8.00 | +200.0K | 10.09M | +2% | +$1.60M |
| DM | 2023-03-14 | 2023-03-10 | ZYME | Klompas Neil A | Pres, COO | M - OptEx | $0.00 | +5,208 | 17.3K | +43% | $0 |
| D | 2023-03-14 | 2023-03-10 | ZYME | Klompas Neil A | Pres, COO | S - Sale+OE | $7.83 | -2,977 | 17.0K | -15% | -$23.3K |
| MI | 2023-01-23 | 2023-01-19+ | ZYME | EcoR1 Capital, LLC | 10% | P - Purchase | $9.70 | +307.5K | 9.72M | +3% | +$2.98M |
| MI | 2023-01-18 | 2023-01-13+ | ZYME | EcoR1 Capital, LLC | 10% | P - Purchase | $9.84 | +985.1K | 9.58M | +11% | +$9.70M |
| MI | 2023-01-12 | 2023-01-10+ | ZYME | EcoR1 Capital, LLC | 10% | P - Purchase | $7.67 | +1.03M | 8.49M | +14% | +$7.87M |
| DA | 2022-12-23 | 2022-11-10 | ZYME | Josephson Neil | Chief Medical Off | M - OptEx | $0.00 | +5,885 | 16.9K | +53% | $0 |
| DA | 2022-12-23 | 2022-11-10 | ZYME | Josephson Neil | Chief Medical Off | S - Sale+OE | $8.10 | -2,475 | 14.4K | -15% | -$20.0K |
| DA | 2022-12-23 | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $6.01 | -887 | 1,333 | -40% | -$5,331 |
| DA | 2022-12-23 | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | M - OptEx | $0.00 | +1,550 | 2,220 | +231% | $0 |
| D | 2022-12-14 | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | S - Sale+OE | $6.01 | -887 | 1,333 | -40% | -$5,331 |
| D | 2022-12-14 | 2022-12-12 | ZYME | Astle Christopher | SVP, CFO | M - OptEx | $0.00 | +1,550 | 2,220 | +231% | $0 |
| D | 2022-11-14 | 2022-11-10 | ZYME | Josephson Neil | Chief Medical Off | M - OptEx | $0.00 | +5,885 | 16.9K | +53% | $0 |
| D | 2022-11-14 | 2022-11-10 | ZYME | Josephson Neil | Chief Medical Off | S - Sale+OE | $8.10 | -2,475 | 14.4K | -15% | -$20.0K |
| AI | 2022-10-18 | 2022-10-13 | ZYME | Redmile Group, LLC | 10% | P - Purchase | $5.03 | +30.5K | 6.08M | +0.5% | +$153.3K |
| I | 2022-10-17 | 2022-10-13 | ZYME | Redmile Group, LLC | 10% | A - Grant | $5.03 | +30.5K | 6.08M | +0.5% | +$153.3K |
Purchase Sale Sale after option exercise All abbreviations